

Bevacizumab

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



Not qualified for an ESMO-MCBS credit



**Serious and disabling adverse effects**



**Other adjustments**



Bevacizumab

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response


**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Thoracic Malignancies  
 Therapeutic Indication: First-line, unresectable advanced, metastatic or recurrent NSCLC other than predominantly squamous cell histology  
 Experimental Arm: Bevacizumab + Paclitaxel + carboplatin  
 Control Arm: Paclitaxel + carboplatin

